Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DOSTARLIMAB vs DOXORUBICIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DOSTARLIMAB vs DOXORUBICIN: Safety Overview

Metric DOSTARLIMAB DOXORUBICIN
Total FAERS Reports 893 82,754
Deaths Reported 130 15,653
Death Rate 14.6% 18.9%
Hospitalizations 441 28,630
Average Patient Age 65.8 yrs 50.5 yrs
% Female Patients 91.6% 53.9%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer GlaxoSmithKline LLC Hikma Pharmaceuticals USA Inc.
Route INTRAVENOUS INTRAVENOUS
Marketing Status N/A Discontinued